Antibody Persistence 10 Years after 1st and 2nd Doses of 23-Valent Pneumococcal Polysaccharide Vaccine (PN23), and Immunogenicity and Safety of 2nd and 3rd Doses in Older Adults

被引：0
|
作者：
Manoff, S. [1 ]
McFetridge, R. [1 ]
Liss, C. [1 ]
Marchese, R. [1 ]
Raab, J. [2 ]
Rueda, A. [3 ]
Musher, D. [3 ]
机构：
[1] Merck, N Wales, PA USA
[2] PPD, Wayne, NJ USA
[3] VA Med Ctr, Houston, TX USA
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2010年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [1] Antibody persistence 10 years after 1st and 2nd doses of 23-valent pneumococcal polysaccharide vaccine (PN23), and immunogenicity and safety of 2nd and 3rd doses in older adults
    Manoff, S.
    McFetride, R.
    Liss, C.
    Marchese, R.
    Rabb, J.
    Rueda, A.
    Musher, D.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E454 - E454
  • [2] Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults
    Musher, Daniel M.
    Manoff, Susan B.
    McFetridge, Richard D.
    Liss, Charles
    Marchese, Rocio D.
    Raab, Jennifer
    Rueda, Adriana M.
    Walker, Monica L.
    Hoover, Patricia A.
    HUMAN VACCINES, 2011, 7 (09): : 919 - 928
  • [3] Pneumococcal polysaccharide 23-valent vaccine: Long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults
    Grabenstein, John D.
    Manoff, Susan B.
    VACCINE, 2012, 30 (30) : 4435 - 4444
  • [4] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
    Jackson, Lisa A.
    Gurtman, Alejandra
    Rice, Kathryn
    Pauksens, Karlis
    Greenberg, Richard N.
    Jones, Thomas R.
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    VACCINE, 2013, 31 (35) : 3585 - 3593
  • [5] 1ST AND 2ND DOSE ANTIBODY-RESPONSES TO PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN INFANTS
    KOSKELA, M
    LEINONEN, M
    HAIVA, VM
    TIMONEN, M
    MAKELA, PH
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1986, 5 (01) : 45 - 50
  • [6] Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Administered Concomitantly with a 23-Valent Pneumococcal Polysaccharide Vaccine in Adults Aged 60 Years and Older
    Zhu, Zhongkui
    Sun, Jianwen
    Xie, Yan
    Lu, Xi
    Tang, Wanqin
    Zhao, Yanwei
    Shen, Lu
    Liu, Huaxian
    Yu, Yang
    Zhou, Siliang
    Huo, Liqun
    Jiao, Peng
    Jiang, Xiaoli
    VACCINES, 2024, 12 (08)
  • [7] THE 1ST, THE 2ND, AND THE 3RD PINEAL-GLAND
    REITER, RJ
    NEUROENDOCRINOLOGY LETTERS, 1986, 8 (01) : 1 - 4
  • [8] THERMAL DISTRIBUTIONS OF 1ST, 2ND AND 3RD QUANTIZATION
    MCGUIGAN, M
    PHYSICA A, 1989, 158 (01): : 546 - 554
  • [9] Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12-to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine
    Thisyakorn, Usa
    Chokephaibulkit, Kulkanya
    Kosalaraksa, Pope
    Benjaponpitak, Suwat
    Pancharoen, Chitsanu
    Chuenkitmongkol, Sunate
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (07) : 1859 - 1865
  • [10] IMMUNOGENICITY AND SAFETY OF 4 DOSES OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOLLOWED BY 1 DOSE OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS AGED ≥2 YEARS: AN OPEN LABEL CLINICAL TRIAL
    Cordonnier, C.
    Ljungman, P.
    Juergens, C.
    Maertens, J.
    Selleslag, D.
    Sundaraiyer, V.
    Clarke, K.
    Gruber, W. C.
    Scott, D. A.
    Schmoele-Thoma, B.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S82 - S83
12345